Document:

Exhibit 10.6
Vital Health Technologies, Inc.
Form 10-KSB
File No. 000-15243

                  COLLATERAL PATENT ASSIGNMENT

THIS COLLATERAL PATENT ASSIGNMENT (this "Assignment"), made as of
the 13 day of August 1998, by and between (Assignor") Vital Heart
Systems, Inc. a Minnesota corporation and Vital Health
Technologies, LLC a Minnesota Limited Liability Company
(Assignee).

                           WITNESSETH:

WHEREAS, Assignor and Assignee are parties to a certain Note and
Security Agreement, dated August 13, 1998 (together with any and
all amendments now or hereafter made thereto, hereinafter called
the "Loan Agreement" which provides for (1) Assignee from time to
time to extend Credit to or for the account of Assignor and (2)
the grant by Assignor to Assignee of a security interest in
certain of Assignor's assets, including, without limitation its
U.S. patents; and

WHEREAS. Assignee has required, as a condition to advancing loans
to Assignor under the Loan Agreement that Assignor execute and
deliver to Assignee this Assignment;

NOW THEREFORE, consideration of the premises, set forth herein
and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, Assignor agrees as
follows:

     1. Incorporation of Loan Agreement. The Loan Agreement and
the terms and provisions thereof are hereby incorporated herein
'in their entirety by this reference. Terms used herein that are
not defined in this Agreement shall have the meanings ascribed to
them in the Loan Agreement.

     2. Collateral Assignment of Patents. To secure the complete
and timely satisfaction of all of the Obligations (as defined in
the Loan Agreement and hereinafter called the "Obligations"),
Assignor hereby grants conveys and assigns to Assignee, as and by
way of a first mortgage and security interest having priority
over all other security interests, with power of sale, to the
extent permitted by law, upon the occurrence and during the
continuation of an Event of Default (as defined in the Loan
Agreement and hereinafter called an "Event of Default") all of
Assignor's right, title, and interest in and to all of its now
owned or existing and filed and hereafter acquired or arising and
filed:

     1.   Patents and patent applications (hereinafter called the
          "Patents") (including. without limitation. the inventions and
          improvements described and claims therein) listed on Schedule A
          attached hereto, (hereinafter called Patents);

     2.   The reissues, divisions, continuations, renewals,
           extensions, continuations-in-part and improvements thereof;

     3.   All income, royalties, damages, and payments now and
          hereafter due and/or payable under and with respect thereto,
          including, (without limitation) damages and payments for past or
          future infringements thereof;

     4.   The right to sue and recover for past, present, and future
          infringements thereof;

     5.   All rights corresponding thereto and throughout the world; and

     6.   All other proceeds and products of the foregoing, including
          (without limitation) any rights pursuant to its agreements with
          any other party relating thereto.

                     				      E-44
<PAGE>

The items referred to in items 1 through 6 are hereinafter called
the "Patent Rights.''

     3. Restrictions on Future Agreements. Assignor agrees that,
until the Obligations are satisfied in full and the Loan
Agreement is terminated, and except as may otherwise be provided
in the Loan Agreement, Assignor shall not without Assignee's
prior written consent:

     1.   enter into any agreement (for example, a license
          agreement) that is inconsistent with Assignor's
          obligations under this Assignment; or
     2.   take any action or permit any action to be taken by
          others subject to its control,  including licensees, or
          fail to take any action (excluding nonpayment of U.S.
          maintenance fees on Patents which are not necessary or
          useful in the operation of Assignor's business or
          operations) if doing so or not doing so would impair
          the validity or enforcement of the Patent Rights.

     4. Covenants and Warranties. Assignor represents, warrants,
and covenants that:

     1.   The Patents are subsisting, have not been adjudged
          invalid or unenforceable in whole or in part, and are
          not currently being challenged in any way;

     2.   None of the Patents has lapsed or expired;

     3.   No claim has been made that the use of any of the
          Patents in the conduct of Assignor's business
          constitutes an infringement of any senior or dominate
          U.S. patent or other intellectual property right;

     4.   Assignor owns the entire right, title, and interest in
          and to each of the Patents free and clear of any liens
          and encumbrances of every kind and nature, except for
          the rights granted by Assignor pursuant to this
          Agreement; and

     5.   Assignor shall continue to use, until the obligations
          shall have been satisfied in full and the Loan
          Agreement shall have been terminated, proper statutory
          notice in connection with its exercise of the Patents.

     5. New Patents and Licenses. If before the Obligations are
satisfied in full, Assignor obtains rights to any new patentable
inventions, Patents or patent applications, or any reissue,
division, continuation, renewal, extension, or continuation-in-
part of any Patent or any improvement on any Patent, the
provisions of Section 2 above shall automatically apply thereto
and Assignor shall give to Assignee written notice thereof.
Assignor hereby authorizes Assignee to modify this Assignment by
amending Schedule A to include such rights.

     6. Royalties; Terms. Assignor hereby agrees that the use by
Assignee of the Patent Rights shall be worldwide and without any
liability for royalties or other related charges from Assignee to
Assignor. The term of the assignments granted herein shall extend
until the earlier of (1) the expiration of all Patent Rights or
(2) payment in full of the Obligations and termination of the
Loan Agreement.

     7. Grant of License to Assignor. Assignee hereby grants to
Assignor the royalty-free, exclusive, nontransferable right and
license to make, have made, use, and sell the inventions
disclosed and claimed in the Patents for Assignor's own benefit
and account and for none other. Such right and license shall be
exercisable by Assignor only until the occurrence of an Event of
Default. Except as otherwise permitted by Loan Agreement,
Assignor agrees not to sell or assign its interest in, or grant
any sublicense under, the right and license granted to Assignor
in this Section without the prior written consent of Assignee.

     8. Assignee's Right to Inspect.   Subject to existing
agreements with respect to the confidentiality of certain aspects
of the Patent Rights, Assignee shall have the right at any
reasonable time and from time to time, to inspect Assignor's
premises and to examine Assignor's books, records, and
operations.

     9. Termination of Assignee's Security Interest. This
Assignment is made for collateral purposes only. Upon payment in
full of the Obligations and termination of the Loan Agreement,
all remaining right title, and interest in and to the Patent

                 				      E-45
<PAGE>

Rights shall automatically revert to Assignor.  In such event,
Assignee shall execute and deliver to Assignor all termination
statements and other instruments as may be necessary or proper to
terminate Assignee's security interest in and to revest In
Assignor all right, title, and interest in and to the Patent
Rights, subject to any prior disposition thereof that may have
been made by Assignee pursuant hereto or pursuant to the Loan
Agreement

     10. Duties of Assignor. Until the Obligations are satisfied
in full and the Loan Agreement is terminated, Assignor shall:

     1.   Prosecute diligently any patent application included in
          the Patent Rights pending as of the date hereof or
          hereafter filed;

     2.   Make application on unpatented but patentable
          inventions, as appropriate giving due consideration to
          value, importance, cost and opinion of counsel as to
          patentability; and

     3.   Preserve, maintain, and enforce against infringement
          all Patent Rights (other than nonpayment of maintenance
          fees on Patents which are not necessary or useful in
          the conduct of Assignor's business or operations).

Any expenses incurred in connection with such applications shall
be borne by Assignor. Assignor shall not abandon any pending
Patent application or patent without the written consent of
Assignee which, consent shall not be unreasonably withheld.

     11. Assignee's Right to Sue. After the occurrence of an
Event of Default and so long as such Event of Default has not
been waived, and after the provision by Assignee of written
notice to Assignor of Assignee's intention to enforce its rights
and claims in the Patent Rights, Assignee shall have the right,
but shall in no way be obligated, to bring suit and take other
action in its own name to enforce or otherwise protect, preserve,
or realize upon the Patent Rights. If Assignee shall commence any
such suit or take any such action, Assignor shall, at the request
of Assignee, do any and all lawful acts and execute any and all
proper documents required by Assignee in aid of such action.
Assignor shall, upon demand, reimburse and indemnify Assignee for
all costs and expenses incurred by Assignee in the exercise of
its rights under this Section 11.

     12. Waivers. No course of dealing between Assignor and
Assignee, nor any failure to exercise or delay in exercising, on
the part of the Assignee, any right, power, or privilege
hereunder or under the Loan Agreement shall operate as a waiver
thereof. No single or partial exercise of any right, power, or
privilege hereunder or under the Loan Agreement shall preclude
any other or further exercise thereof or the exercise of any
other right, power, or privilege.

     13. Severability.  The provisions of this Assignment are
severable and if any clause or provision shall be held invalid or
unenforceable in whole or in part in any jurisdiction then such
invalidity or unenforceability shall affect only such clause or
provision, or part thereof, in such Jurisdiction, and shall not
in any manner affect such clause or provision in any other
Jurisdiction, or any other clause or provision of this
Assignment.

     14. Modification.  This Assignment cannot be altered,
amended, or modified in any way, except as specifically provided
with respect to the additions referred to in Section 5 hereof or
by a writing signed by the parties hereto.

     15. Cumulative Remedies. All of Assignments rights and
remedies with respect to the Patent Rights, whether established
hereby or by the Loan Agreement, or by any other agreements or by
law, shall be cumulative and may be exercised individually or
concurrently. Assignee shall have, in addition to all other
rights and remedies given it by the terms of this Assignment, all
rights and remedies allowed by law and the rights and remedies of
a secured party under the Uniform Commercial Code as enacted in
any jurisdiction in which the Patent Rights may be enforced.

     16. Power of Attorney. Assignor hereby authorizes Assignee to:

                     				      E-46
<PAGE>

     1.   Make, constitute, and appoint any representative of
          Assignee as Assignee may select, in its sole
          discretion, as Assignor's true and lawful attorney-in-
          fact, with power to endorse Assignor's name on all
          applications. documents, papers, and instruments
          necessary or desirable for Assignee to give effect to
          the provisions of this Assignment and the intent of the
          parties hereto;

     2.   Take any other actions with respect to the Patent
          Rights consistent with this Assignment, as Assignee
          deems in the best interest of Assignee;

     3.   Following the occurrence of an Event of Default, grant
          or issue any exclusive or nonexclusive license under
          the Patent Rights to anyone; or

     4.   Following the occurrence of an Event of Default,
          subject to the terms of any existing license agreement,
          assign, pledge, convey or otherwise transfer title in
          or dispose of the Patent Rights to anyone.

Assignee hereby ratifies all that such attorney shall lawfully do
or cause to be done by virtue hereof. This power of attorney
shall be irrevocable until the Obligations are satisfied in full
and the Loan Agreement is terminated.

     17. Effect on, Loan Agreement Assignor acknowledges and
agrees that this Assessment is not intended to limit or restrict
in any way the rights and remedies of Assignee under the Loan
Agreement but rather is intended to facilitate the exercise of
such rights and remedies.

     18. Binding Effect; Benefits. This Assignment shall be
binding upon Assignor and its respective successors and assigns
and shall inure to the benefit of Assignee, its nominees,
successors, and assigns.

     19. Governing Law. This assignment shall be deemed to have
been executed and delivered in Minnesota, and shall be Governed
by and construed in accordance with the internal laws (as opposed
to conflicts of law provisions) of Minnesota.

     WITNESS the due execution hereof as of the date first above
written.

Vital Heart Systems. Inc.
By:/s/John Mondati
      John Mondati
       Director

Accepted:

Vital Health Technologies, L.L.C.
By : /s/William Kieger

                      	 			      E-47
<PAGE>Exhibit 10.7
Vital Health Technologies, Inc.
Form 10-KSB
File No. 000-15243

             Settlement of Convertible Secured Note

Date of Note:       September 1, 1998
Debtor:             Vital Heart Systems, Inc.
Secured Party:      Vital Health Technologies, L.L.C.
Amount              Advances up to $500,000
Interest rate       10% per annum with an additional 3% in the
event of default

The above parties agree to the following:

Whereas; Vital Heart Systems, Inc. recognizes an advance total of
$151,264 as of October 18, 2000 and that the note has been in
default since August 31, 1999 and calls for an additional 3% per
annum interest rate that has not been added to the total.

Vital Heart Systems, Inc. recognizes that the advances include
direct payment of expenses and costs incurred by Vital Heart
Systems, Inc.  In addition, advances include personal services
provided by staff members of Vital Health Technologies, L.L.C.  A
detail accounting of all advances is attached to this agreement.

The conversion of the note to common stock ("Conversion Shares")
is determined by dividing the advance total of $151,264 by the
thirty (30 day average trading price of Vital Heart Systems, Inc.
immediately prior to the date of the merger/acquisition, or
$0.50/share should the thirty (30) day average exceed $50/share.
The trading price of the stock has been between $.001 and $.05
the past 30 days from the date of this agreement.  Assuming the
stock price averages $.05 for the 30 days prior to the
anticipated merger/acquisition date of November 10, 2000, the
amount of common stock according to the conversion formula would
be substantially more than the plan of reorganization has
budgeted and approved by the shareholders of Vital Heart Systems,
Inc.

Therefore; the parties above agree to settle the note for the
amount of budgeted stock remaining following the settlement of
the debt owed to the John Halpern group of creditors, William
Wustenberg and the amount budgeted in accordance with the
agreement with Introl Corporation.  The amount of common stock
remaining is 400,991 shares.

This document has been reviewed and agreed to this 27th day of
October, 2000.

/s/Stephen Muscanto
Director
Vital Heart Systems, Inc.

/s/William Kieger
President
Vital Health Technologies, L.L.C.

                        				      E-48
<PAGE>

Statement
Advances to Vital Heart Systems, Inc.       9/15/00                  10/18/00
Balance January 18, 2000                $ 50,525.00 New balance      114,623
Interest        10%                     $  3,368.00               $      955

Filing fees                                                       $      130
Legal fees                                                        $    4,556
Credit search                           $    456.75
Printy settlement                                                 $   20,000
Halpern settlement                      $  6,225.00
Wustenberg settlement                                             $    1,000

Shareholder letter of notification
Staff
Postage                                 $   434.88
CEDE                                    $ 1,299.85
Envelopes - paper                       $   244.94
Shareholder meeting mailing
Staff                                   $ 5,500.00
Postage                                 $   945.00
Envelopes - paper                       $   489.88
Shipping                                $   164.50
ADP/CEDE                                $ 4,797.50
Ramada Inn                              $   171.30
Storage/rent                            $ 4,000.00                   $ 500
Consulting services
Creditor settlement            5                      10
Audit preparation             45                      10
Preparation of documents      60                      20
Shareholder communication     70                       5
                             180  200  $ 36,000.00    45   200   $  9,000
Transfer agent                                                   $    500
This period                            $ 60,729.60               $ 35,686
End balance                            $   114,623               $151,264
Settlement
Projected                              $   169,757
Conversion @   $ 0.05        shares      3,395,132

                           				      E-49
<PAGE>

Vital Health Technologies

STATEMENT

Expenses related to loan agreement with Vital Heart Systems, Inc.
January 18, 2000

Advances to VHS
Cash
$1,455              11-9-99
$2,690               1-6-99
$2,690               1-6-99
$2,690               1-6-99

Storage
$7,000              $500 per month

Consulting services

$ 20,000       Shareholder and creditor communications 100 hours
          		   @ $200 per hr
$ 14,000       Management and documentation of corporate records,
          		   files and books

Total              $50,525

     3434 Lexington Ave.  N.  Suite 200, Shoreview, MN 55126
          651-484-3477 phone           651-484-6184 fax

                      				      E-50
<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00020-of-00352.parquet"}]]